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Abstract
The use of cell lines or animal models has significant disadvantages when dealing with a set of heterogeneous diseases such
as epithelial ovarian cancer. This has clinical relevance in that biomarkers developed using cell line or animal models are
often not transferable to the clinical setting. In this study, we describe the development of a robust protocol for developing
primary cultures of ovarian cancer which will overcome some of these difficulties. Women undergoing surgery for ovarian
cancer were recruited and samples of ascites and solid tumour deposits were used to develop primary cultures. Cells were
characterised using a panel of immunofluorescent antibodies prior to use in a variety of assays including functional
assessment of DNA repair pathways. During the four year study period, viable cultures, confirmed to be epithelial in origin
were generated from 156 of 172 (91%) cases recruited. Characterisation was carried out using a panel of antibodies
including pancytokeratin, CA125, EpCAM, MOC-31, D2-40 and vimentin. Senescence occurred between the 2nd and 8th
passages in all cultures except one in which spontaneous immortalization occurred. Cells could be successfully cultured
even after a period of storage at 4uC and cultured cells were capable of being used for a variety of applications including
functional assays. Upon functional assessment there was minimal intra-tumour heterogeneity. It is therefore possible to
derive viable ovarian cancer cell cultures in the majority of patients undergoing surgery. Cells cultured directly from patient
cancers provide an accurate and highly diverse model.
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Introduction
Ovarian cancer is the leading cause of gynaecological cancer
mortality worldwide [1] and despite much research into the
treatment of ovarian cancer the overall mortality has changed little
over the past 20 years with a 5-year overall survival of 30–39% [2].
It has long been recognised by clinicians that ovarian cancer is a
set of heterogeneous diseases but despite this ovarian carcinoma
continues to be treated clinically as a single disease using a
combination of debulking surgery and platinum-based chemo-
therapy. The observed variation in the clinical behaviour of
ovarian cancer alongside the growing data reporting molecular
heterogeneity suggests that a heterogeneous model for the study of
ovarian cancer is long overdue. The emerging concept of
personalised medicine based upon biomarkers of response to
novel treatments targeting specific defects in tumour DNA repair
is only possible if biomarkers can be tested using a realistic model.
Established cell lines provide an invaluable tool for studying
biological functions at the molecular and cellular level. Existing
human ovarian cancer cell lines possess the advantage of high
proliferative capacity, clonogenecity and extended life span in
culture. However, most have acquired significant genetic alter-
ations from their cells of origin, including deletion of important
regulatory cell cycle genes supporting immortality. Additionally,
there is evidence to suggest that many cell lines contain significant
misidentification, duplication, and loss of integrity [3].
Primary cells isolated from patients are often considerably
different from established cell lines of similar origin. The ability to
culture and characterise freshly isolated OSE (ovarian surface
epithelium) and EOC (epithelial ovarian cancer) cells from patients
provides an important experimental system that has the potential
to resemble the patient situation more accurately [4,5].
There are two sources of clinical material which have been used
to generate primary cultures in ovarian cancer: ascitic fluid and
solid tumour tissue. Gene expression studies have indicated
different biological profiles in the cancer cells derived from these
two sources from the same patient in terms of metastasis, invasion
and angiogenesis [6]. Ascitic fluid has several advantages over solid
tumour tissue in generating primary cultures. Ascitic fluid is
relatively easy to obtain and culturing the suspended cells is
technically straight forward. Ascitic cultures have been shown to
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generate a homogeneous epithelial cell rich population compared
to those obtained from solid tissues. Significant proportions of
patients with ovarian cancer present at an advanced stage and
have large volumes of ascitic fluid which can be obtained during
surgery or paracentesis. However, as the majority of patients with
large volume ascites have tumours of a high grade serous
histological subtype, only sampling ascites will underrepresent
the other histological subtypes. Culture of solid tumour, particu-
larly in the absence of ascites is therefore also required to capture a
representative group of samples.
Primary cell culture from either source could provide a resource
for testing the molecular profile and performing functional studies
of individual cancers. In recent years the association between
tumour molecular heterogeneity, survival and/or response to
treatment has been acknowledged [7] and has fuelled the search
for biomarkers to predict response to novel therapies targeting
DNA repair pathways deregulated in ovarian cancer.
Several methods for the culture of primary ovarian cancer cells
isolated from ascites have been described [8]. These methods
however require complex multi-step procedures. Dunfield et al and
Shepherd et al describe a more simple and reliable culture method
involving mixing ascites directly with medium which results in
epithelial cell culture [4,9]. This technique has been adapted by
our group for use in research into the functional status of DNA
repair mechanisms and here we report our experience of this
technique.
Methods
Ethics statement
The study was approved by local ethics committee (UK IRAS
North West ethics committee - 12/NW/0202) and all patients
gave written informed consent.
Reagents
Rucaparib was a gift from Clovis (USA) and is a potent inhibitor
of PARP-1 and 22 proteins (with an inhibition constant of
,5 nM). All other chemicals and tissue culture reagents were from
Sigma-aldrich (Sigma-aldrich, UK), unless otherwise stated.
Cell Culture
Sample collection. Ascites and solid tissue was collected
from consented patients undergoing surgery for ovarian cancer at
the Queen Elizabeth Hospital, Gateshead, UK. Clinical details
were recorded and specimens registered and handled in accor-
dance with the Human Tissue Act. Samples were assigned a PCO
(Primary Culture Ovary) reference number to retain anonymity.
Sample transport and preparation. Ascites was aspirated
directly from the patient into a sterile suction bottle. Solid tumour
was placed into a sterile universal containing culture medium
(RPMI 1640 medium supplemented with 20% FCS, 20 mM L-
glutamine and 1% penicillin and streptomycin) pre-warmed to
37uC. Samples were transported from the hospital to the lab
immediately in compliance with UK Category B regulations
UN3373.
Primary Culture from ascites. Cell culture was performed
using an aseptic technique in a containment level II laminar flow
microbiological safety cabinet. 20 ml of ascites was added to 20 ml
of warmed culture medium (RPMI with 20% FCS, as above) in
T75 flasks (Corning, USA) and incubated at 37uC, 5% CO2, 95%
humidified air. The medium was aspirated and 13 ml of warmed
fresh medium was replaced on day 3 to 5. The medium was
replaced every 4 to 5 days until the cells approached confluence.
Cells were passaged, frozen and thawed as previously described
[10]. Cell cultures were quarantined in a primary incubator to
await formal pathological examination results and to ensure that
infected samples were not introduced into general culture.
Primary culture from solid tumour. Once in the labora-
tory, the solid tumour was dissected into ,3 mm3 pieces using a
sterile scalpel and transferred to T25 flasks containing sufficient
collagenase/dispase (Roche, UK) solution (1 mg/1 ml in full
medium) to fully immerse the sample. The cells were incubated for
2 hours at 37uC on an orbital shaker (IKA-Vibrax-VKR) at 26G.
The cell suspension was transferred to a universal container,
centrifuged at 4006G for 5 minutes, PBS washed, re-suspended in
full medium and placed in a T25 flask for 30 minutes to allow
fibroblast seeding. The epithelial cell suspension was transferred to
a T25 flask for on-going cell culture.
Culture optimisation
Direct culturing onto coverslips. Time from collection to
functional assessment can be up to 14 days. To reduce the length
of culture and handling prior to use, media and ascitic fluid (1:1
v:v) was added directly onto sterile cover slips for immediate
analysis.
Cytospinning. Ascitic fluid was cytospun directly onto
microscope slides after optimisation of centrifugation speed,
sample volume and enrichment of ascitic fluid using the addition
of red cell lysis buffer. Following cytospining, slides were air dried,
fixed with 100% methanol and stored at 220uC for later
characterisation.
Characterisation
Ovarian cancer is a set of heterogeneous diseases. Additionally,
ascitic fluid contains a variety of cell types and a single marker is
therefore insufficent to reliably differentiate epithelial ovarian
cancer cells from other cell types. A characterisation panel
consisting of cell culture morphology, immunofluorescent staining
of fixed cells, as well as standard pathological and immunohisto-
chemistry examination was combined to ensure accurate epithelial
characterisation of every culture.
Morphology. Morphological features were studied under an
Olympus CK40 inverted microscope at 206 magnification.
Images were captured using VisiCam software (VWR, USA).
Immunofluorescence. Standard techniques for immunoflu-
orescence were used to stain for pancytokeratin, epithelial cell
adhesion molecule (EpCAM), cancer antigen 125 (CA125),
epithelial related antigen (MOC-31), D2-40 and vimentin,
Table 1. None of the positive markers are uniformly expressed
in all EOC cells but interpreted in combination enable the
selection of appropriate cultures.
Formal histopathology
Formal pathological and cytological examination of ascitic and
solid tumour specimens from patients donating PCO samples was
performed and used to further characterise the cultures.
When all characterisations were in keeping with epithelial
ovarian origin, the samples were then used in subsequent
experiments. Where results were inconsistent with epithelial
origin, cultures were discarded.
ImagestreamX characterisation
Established PCO cultures and fresh ascites. PCO cells,
cultured using the methods above, were trypsinised, fixed with
0.4% paraformaldehyde for 20 minutes at 4uC, and permeabilised
with BD Phosflow Perm/wash I (BD Biosciences, USA; 1:10 v:v
distilled water).
Ovarian Cancer Primary Cultures
PLOS ONE | www.plosone.org 2 March 2014 | Volume 9 | Issue 3 | e90604
For fresh ascites, ten ml of ascitic fluid was filtered to exclude
large debris (180 mm pore nylon filter, Millipore, UK). As ascitic
fluid is frequently contaminated with blood, the addition of a
fixative containing red cell lysis buffer (1:5 v:v BD Phosflow Lyse/
Fix red cell lysis buffer, BD Biosciences, USA) enabled depletion of
red blood cells. Cells were permeabilised with BD Phosflow Perm/
wash I and the sample further enriched by depletion of white
blood cells using EasySep Human CD45 Depletion Kit (STEM-
CELL technologies, France), as per manufacturer’s instructions.
All samples were then incubated with immunoflourescent–
labelled antibodies for 12 hours at 4uC including pancytokeratin,
EpCAM, CA125, DRAQ5 nuclear stain and common leucicytoe
antigen (CD45) to identify white blood cells. Samples were
processed using ImagestreamX (Amnis, USA) with IDEAS
software utilised to quantify the proportion of cells expressing
the three epithelial markers, as well as providing an assessment of
co-expression.
Growth and Cytotoxicity assays
SRB. A routine sulforhodamine B (SRB) assay was used to
assess cytotoxicity and cell growth as previously described [11].
Briefly, cells were seeded at a concentration of 1000 cells/well and
after adherence, treated with various concentrations of rucaparib
for 10 days before fixation, staining and spectrophotometer
assessment.
Clonogenic Assays. Clonogenic assays are considered gold
standard for the assessment of cytotoxicity. 50,000 cells/well were
seeded in a 6 well plate for 24 hours. Cells were then incubated for
24 hours with various concentrations of the cytotoxic agent before
reseeding at concentrations of 2,500, 5,000 and 10,000 cells for
each drug treatment. Cells were incubated at 37uC for 14 days.
The medium was aspirated, plates were washed in PBS and then
fixed using the Carnoy’s fixative (acetic acid: methanol 1:3 v/v)
followed by staining with 1% crystal violet.
Agar clonogenics. 50,000 cells were seeded into wells
containing media and treated as above for 24 hours in agarose
media. Cells were then trysinised, washed and re-seeded in semi-
solid agarose (Promega, UK) media, at a variety of concentrations,
and incubated for 14 days. Colonies were stained using 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT).
Cell transfection
Luciferase expressing plasmid pGL2 (Promega, USA) was
transfected using two methods. Firstly, the manufacturer’s protocol
(Invitrogen, USA) for transfecting cells with lipofectamine TM
LTX with Plus reagent was used to transfect PCO cultures with 1–
6 mg of DNA per well. Secondly, 250 ml of PCO cell suspension
containing 16106 cells/ml was mixed with 1–5 mg of pGL2
plasmid in 4 mm electroporation cuvettes (Eurogentec, Belgium).
Electroporation was carried out using an EPI-2500 electroporator
at 100–500 volts. The transfectants from both methods were
harvested 48 hours after transfection and assayed for luciferase
activity.
Furthermore PCO cultures were transfected using MIS-
SIONTM shRNA lentiviral transduction particles (Sigma-aldrich,
USA), as per manufacturer’s protocol.
Homologous recombination assay
Cells were seeded onto glass cover slips and treated with 2Gy
ionising radiation and rucaparib at 10 mM concentration for
24 hours to induce double strand breaks (DSB). All experiments
were performed alongside untreated controls with equivalent 0.1%
DMSO. Cells were then fixed and rehydrated prior to staining
with 1:100 mouse monoclonal anti-cH2AX (Upstate, Millipore
Corp., USA) and 1:100 goat polyclonal anti-Rad51 (Calbiochem,
EMD Biosciences, Inc., USA) antibodies with appropriate
secondary fluorochrome conjugated antibodies, as previously
described [5].
Image J counting software [12,13] was used to count cH2AX
and Rad51 nucleic foci. Cells were classed as homologous
recombination (HR) competent if there was more than a 2 fold
increase in Rad51 foci after DNA damage, confirmed by a 2 fold
increase in cH2AX.
Results
Generation of primary cultures from ascites
Ascites was collected from 172 ovarian cancer patients
undergoing primary (67%) or delayed primary surgery (following
three to four cycles of platinum-based neo-adjuvant chemother-
apy; 33%) between 2008 and 2013. Viable cultures were
generated in 166/172 (97%) cases. Erythrocytes and cellular
debris from ascites did not adhere to the culture flask and were
Table 1. Antibodies used for cell characterisation.
Marker Description Concentration Company
Pancytokeritin PCO samples were classified to be epithelial in origin if more than 95% of cells stained with mouse
monoclonal anti-pancytokeratin FITC–conjugated antibody
1:100 Upstate Millipore
Corp., USA
EpCAM Epithelial origin was confirmed with positive staining for mouse monoclonal anti-CD326 Alexafluor
488–conjugated antibody
1:100 Biolegend, USA
(CA125 CA125 is expressed in 80% of epithelial ovarian cancers [22]. Expression was assessed using mouse
monoclonal anti-CA125 antibody and Alexafluor 546 goat anti-mouse secondary antibody.
1:100 (Primary) Abcam, USA
MOC-31 MOC-31 is present on most normal and malignant epithelia [23] enabling discrimination from
mesothelial derived tumours. Expression was assessed using mouse monoclonal anti-MOC-31
antibody and Alexaflour 596 goat anti-mouse secondary antibody.
1:100 (Primary) Dako, Germany
D2-40 Anti-D2-40 identifies an O-linked sialoglycoprotein present on germ cell tumors but not epithelial
cells [24]. Expression was assessed using mouse monoclonal anti-D2-40 antibody and goat
anti-mouse Alexafluor 596 secondary antibody
1:100 (Primary)) Dako, Germany
Vimentin Marker commonly used to detect epithelial-mesenchyman transition (EMT). Expression was assessed
using rabbit monoclonal anti-vimentin antibody, clone EPR3776 and Alexafluor 488 goat anti-rabbit
secondary antibody
1:100 (Primary) Abcam, USA
doi:10.1371/journal.pone.0090604.t001
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removed following media change. In general the appearance of
each culture was that of a cobblestone monolayer pattern, Figure 1
(A), as described by Dunfield et al [4]. Ascitic fluid is composed of
multiple cellular components and in order to confirm exclusive
growth of cancer cells characterisation of cultured cells is required.
Immunoflourescent characterisation of the cultures was carried
out using the panel of antibodies to detetct expression of
pancytokeratin CA125, EpCAM, MOC-31, D2-40 and Vimentin,
Figure 1 (B-F). 10/166 (6%) were rejected as they failed to
demonstrate greater than 95% cytokeratin positivity. The overall
success rate therefore for creating ascitic epithelial primary
cultures from patients undergoing surgery was 156/172 (91%).
Routine histopathological examination of FFPE tissue from each
patient was carried out, Table 2. The most predominant
histological subtype was high grade serous cancer.
In a subset of samples, immunoflourescent assessment of CA125
expression in the PCO sample was compared with the CA125
expression on immunohistochemical analysis of FFPE tissue from
the same patient, Figure 2. Correlation of results from the two
assessments was seen in 8/11 (72%) cases. In the remaining three
cases, two showed IHC expression of CA125 only, whilst one
showed IF expression only.
Cellular morphology was studied over time and it was seen that
the majority of cultures were of cobblestone morphology but late
passage cells (typically following passage 4/5) developed a more
mesenchymal phenotype, becoming elongated and exhibiting a
markedly reduced growth rate. Senescence occurred between the
2nd and 8th passages, most commonly between 4th and 5th, thus
rendering further characterisation at late passage impossible.
Cultures were considered unsuccessful when no growth was seen
after 28 days. One culture spontaneously immortalized and has
been grown to more than 20 passages. It is not clear why culture
from ascites is unsuccessful in a proportion of cases, why
senescence occurs at variable passages or why only one culture
has immortalised. It is likely however that this is a consequence of
a lack of essential factors required for growth which are provided
in vivo by the complex interactions within the tumour microenvi-
ronment and which are lacking in the artificial culture environ-
ment.
Culture growth
Growth rates of 30 PCO cultures, grown in RPMI media
supplemented with 20% FCS, were measured by SRB assays using
early passage cells to generate doubling times. Doubling times
between PCO cultures were highly variable with a median
doubling time of 100 hours (range 79 to 195 hours), Figure 3.
However, cells from the same culture tested at different passage
showed minimal variability in doubling time (mean difference of
0.9 hours; SEM 4.8). No correlation was demonstrated between
growth rate, histological subtype or stage of disease at presenta-
tion. The relatively slow growth rate seen may also be a
consequence of the articial culturee environment and lack of
factors from the tumour micronvironment.
Primary culture from solid tumour
In parallel with ascites, solid tissue was collected from 11
patients and processed as described. Establishment of cell cultures
from tissue explants was achieved in 100% of cases. The explant
morphology was lost 72 hours post-seeding as cells acquired a
monolayer cobblestone appearance with time and passaging.
Cultures showed a similar morphological appearance to those
derived from ascitic cell culture, Figure 4. Fibroblast contamina-
tion was minimised by plating the cells for 30 minute incubation
before removing the epithelial rich supernatant and replating,
Figure 5.
Sample transport
Transport optimization. Place of sample collection is
frequently distant from laboratory facilities. In order to use this
model in collaborative translational work successful establishment
of culture following transport needs to be considered. We therefore
Figure 1. Phenotypic appearances of primary cultures. A: Brightfield demonstrating cobblestone monolayer; immunoflourescent images with
antibodies targeted against: B: FITC-anti-pancytokeratin; C: Alexafluor 596 anti-CA125; D: Alexflour 488 anti-EpCAM; E: Alexafluor 596 anti-MOC 31; F:
Alexaflour 596 anti-Vimentin
doi:10.1371/journal.pone.0090604.g001
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compared the success of culture characterization and functional
assays following various transport methods.
Group 1 - Fresh ascites (n=10): transport to the lab with
processing within 6 hours of collection, using the method
described above.
Group 2 - Room temperature samples (n=7): ascites
was stored at room temperature in a sterile container for 24 hours
before mixing 1:1 with media in a flask as above.
Group 3 - Refrigerated samples (n=10): ascites was
stored at 4uC for 24 hours before mixing 1:1 with medium as
above.
Group 4 - Frozen samples (n=6): paired sets of 50 ml
aliquots of ascitic fluid were centrifuged at 400G for 5 minutes.
The resultant cell pellets were frozen, stored at 280uC and
2120uC and thawed at 6 weeks and 6 months.
Successful cultures were attained from all transport groups
however in cases with delayed culture it was preferable to maintain
cultures at 4uC. There was no difference in morphology of the
cultures grown from each group, Table 3.
Ascitic cell pellets (Group 4) stored at 280uC and 2120uC were
thawed at 6 weeks and 6 months. Cultures were successfully grown
from both storage conditions after 6 weeks with no difference
observed in morphology, growth rate or functional assessment.
However, following 6 months storage, a significant difference in
success of subsequent culture from the two conditions was
observed. Ascitic pellets stored at 2120uC were successfully
cultured in 83% cases. No cultures stored at 280uC could be
successfully grown.
Coverslip cultures
The morphological appearance of coverslip cell cultures was
akin to parallel cultures processed using the standard method.
Immunoflourescent characterisation was consistent across all PCO
cases between coverslip and traditional method cultures. Optimal
immunoflourescent staining for characterisation was obtained if
performed more than 24 hours after seeding.
Cytospinning
The optimum parameters to balance maximal cell adherence
with preservation of nuclear morphology were 200 ml of ascitic
fluid (concentration of 106104 cells per ml) cytospun at 806G for
5 minutes. Despite steps taken to deplete the ascitic fluid sample of
unwanted non-epithelial cells and debris, slides remained heavily
contaminated, confirmed by sub-optimal cytokeratin staining and
poor CA125 expression. Contamination made assessment of
morphology, immunoflourescent characterisation and functional
assessment of HR status unsuccessful.
ImagestreamX assessment of PCO cultures
The introduction of ImagestreamX technology with its ability to
combine flow cytometry with high resolution immunoflourescent
Table 2. Patient demographics by histological subtype.
Histological subtype n=
Median age at
diagnosis (years)
Median CA125
(U/ml) FIGO Stage (%)
Remaining disease .1 cm
following surgery (%)
1 2 3 4
High grade serous 83 67 1439 1 1 79 19 18
Clear cell 4 67 187 0 0 67 33 0
Endometrioid 7 64 896 29 0 57 14 14
Carcinosarcoma 5 65 618 0 0 60 40 0
Mucinous 3 58 539 100 0 0 0 0
Low grade serous 5 75 1171 0 0 100 0 20
Dysgerminoma 1 26 90 100 0 0 0 0
Borderline tumour 1 66 180 100 0 0 0 0
Other 14 59 190 0 33 50 17 14
doi:10.1371/journal.pone.0090604.t002
Figure 2. Antigen expression in primary cultures. PCO 158 A: Immunohistochemical detection of CA125 in FFPE tissue; B: Immunofluourescent
detection of CA125 with Alexaflour596 from corresponding primary culture
doi:10.1371/journal.pone.0090604.g002
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microscopy permitted the assessment of expression of a number of
immunofluorescent-labelled markers within individual cells simul-
taneously at high speed and high resolution. Immunoflourescent
detection of the three epithelial ovarian markers (pancytokeratin,
EpCAM and CA125), assessed using standard fixed immunoflu-
orescence and ImagestreamX technology was consistent in 13/15
cases (87%), Table 4. In addition ImagestreamX enabled the
quantification of percentage expression and assessment of co-
expression.
ImagestreamX assessment of fresh ascites samples
Ten ml of fresh ascites was collected and analysed from seven
ovarian cancer patients using ImagestreamX. Cells were classified
as epithelial if they were nucleated, negative for CD45 and positive
for EpCAM, CK or CA125. The epithelial cell population in each
ascitic sample could be divided into a number of sub-populations
based upon the pattern of antibody labelling, Figure 6a and b, and
demonstrated great inter-tumour heterogeneity. The proportion of
cells staining positive for EpCAM was highly variable with a
median of 52% (0–98%). There was no correlation between the
ImagestreamX determined expression of epithelial markers and the
status as determined by fixed immunofluorescence (ROC curve,
not shown, AUC of 0.5). It is possible that some of these
subpopulations may represent non-epithelial cells (ie mesothelial
cells) but it also possible that they are in fact epithelial cells and
undergo phenotypic change as a result of the culture method; or
that the culture method positively selects out subpopulations. Cell
sorting with subsequent molecular profiling of each of the
subpopulations would clarify this and enable further molecular
differences in subsets of EOC to be explored.
Cell transfection
A number of functional assays require transfection of vectors
into cells [14,15]. Despite optimisation, both lipofectamine and
electroporation transfection methods failed to yield a high enough
transfection efficiency for functional assays.
However, cells continued to grow in puromycin media following
transfection using MISSIONTM shRNA lentiviral transduction
particles suggesting successful transfection. Long term transfection
could not be assessed due to the short term life-span of the PCO
cultures.
Functional homologous recombination assays and
cytotoxicity
The RAD51 assay for HR DNA repair status was successfully
performed in all primary cultures which were grown successfully
from all transport groups. HR status for cultures from the same
PCO donor using direct plating onto coverslips and ascitic cultures
were all consistent. Culturing directly onto cover slips reduced the
time taken from collection to determine HR status from
approximately 14 to 5 days.
As expected the GI50 values following treatment with rucaparib
for each PCO culture were variable, however a clear differenti-
ation of sensitive and resistant samples was seen as previously
described [5]. In the majority of cases, as expected, PCO samples
with defective HR status were sensitive to rucaparib, whilst those
with competent HR status were resistant, Table 5.
Despite optimisation of several standard clonogenic techniques,
colony formation was not seen and therefore clonogenic assays
abandoned in PCO cultures. Cell line work has previously
demonstrated a linear relationship between results obtained from
SRB and clonogenics and therefore SRB was adopted as the
standard technique in this study [16].
Discussion
The ability to generate and utilise primary cultures of ovarian
cancer has several advantages over other models including
established cell lines and animal models. It is now recognised that
many cell lines in long term culture will undergo further genetic
aberrations rendering them dissimilar from their tissue of origin.
Furthermore even a large panel of cell lines cannot recapitulate the
Figure 3. Growth curves for 6 representative PCO cultures
(PCO143, 146, 149, 164,167 and 168). The mean and SD of 6
repeats for each time point is plotted, normalised to day 1.
doi:10.1371/journal.pone.0090604.g003
Figure 4. Brightfield images of PCO 163 which was derived from solid tissue explant. A: Passage 0 at 48 hours; B: Passage 0 at 72 hours;
C: Passage 1 at 14 days
doi:10.1371/journal.pone.0090604.g004
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tremendous heterogeneity that is seen in epithelial ovarian cancer.
Many animal models are merely xenografts utilising these cell lines
and therefore retain the same set of problems. Transgenic mouse
models tend to have been generated by integrating a small number
of mutations [17] and therefore do not display the massive
chromosomal instability which is a recognised hallmark of ovarian
cancer [18].
Here we have described our own findings for generating
primary cultures of ovarian cancer, using cells derived from both
ascites and solid deposits of disease. The ability to culture from
both of these materials is important as, dependent upon the
clinical setting, only one of these materials may be available. For
instance, in relapsed disease it is not unusual to see ascites in the
absence of large solid deposits in contrast to the initial presentation
setting where only solid disease may be present. We have reported
a sequential set of samples to demonstrate the success rate for
generating cultures. 156/172 (91%) samples collected resulted in a
viable culture of epithelial cells. This figure is sufficiently high to
justify the feasible use of these techniques in routine clinical
practice if diagnostic tests were developed for use with this
material.
Often, and indeed in our own case, there may be significant
geographical separation between the operating room and the
diagnostic laboratory. The ability to transport samples without loss
of integrity is therefore essential and we have described techniques
demonstrating that these samples can safely be maintained at
either 4uC or 220uC for up to 24 hours before culturing.
Furthermore, the ability to store cultures long term in liquid
nitrogen allows the possibility of collaboration for research or post
hoc diagnostic analysis.
Particularly at high stage when tumours are disseminated
throughout the abdominal cavity and beyond, many tumours will
demonstrate significant intra-tumour heterogeneity [19,20] al-
though often these changes are more related to local stromal
reaction than to the presence or absence of key driver mutations
[21]. The ability to culture both ascites and solid tissue derived
cells allows investigation of intra-tumour heterogeneity although so
far our results suggest that both morphology and outcome of
functional assays is similar in the different subcultures taken from
the same patient. This suggests that HR function is a global
characteristic of the cancer, independent of heterogeneity and
therefore may potentially reflect mutations resulting in dysfunc-
tional HR status as an early event that has driven the cancer
formation.
One of the strengths of developing models of viable cancer cells
is that it allows for the use of functional assays which would not be
possible using FFPE tissue or even fresh frozen tissue. This is likely
to become increasingly important in the development of
Figure 5. Brightfield images of PCO 162 demonstrating the effects of selective seeding. A: Epithelial cell growth from supernatant
removed 30 minutes after initial plating (620 magnification); B: Cells adhering during the initial 30 minute incubation were almost entirely fibroblastic
(610 magnification).
doi:10.1371/journal.pone.0090604.g005
Table 3. Primary culture outcomes following transport.
Sample transport n= Culture success
Passage 1 Passage 2
Group 1 -Fresh collection 75 70 (90%) 64 (85%)
Group 2 - Room temperature 7 5 (71%) 4 (57%)
Group 3 –4 uC 10 9 (90%) 9 (90%)
Group 4 -Frozen 6 weeks 280uC 6 6 (100%) 6 (100%)
2120uC 6 6 (100%) 6 (100%)
6 months 280uC 6 0 0
2120uC 6 5 (83%) 5 (83%)
doi:10.1371/journal.pone.0090604.t003
Table 4. Comparison between the characterisation results
from immunoflourescent microscopy (IF) and ImagestreamX
(ISX).
Sample EpCAM CK CA125
IF ISx IF ISx IF ISx
PCO 1 Negative Negative Positive 79%
Positive
Variable 11%
Positive
PCO 2 Negative Negative Positive 98%
Positive
Variable 4%
Positive
PCO 3 Positive Negative Positive 90%
Positive
Positive 28%
Positive
PCO 4 Negative Negative Positive 84%
Positive
Variable 13%
Positive
PCO 5 Variable 10%
Positive
Variable 35%
Positive
Variable 36%
Positive
doi:10.1371/journal.pone.0090604.t004
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Figure 6. A: ImagestreamX cell plot of representative cells demonstrating the three major cellular sub-populations within ascitic fluid, ; i) CK positive
only, ii) CK and CA125 positive and iii) EpCAM, CK and CA125 positive. B: Sub-populations identified in the epithelial cell population in EOC ascitic
fluid (n = the total number of epithelial cells identified in 10 ml of ascites).
doi:10.1371/journal.pone.0090604.g006
Table 5. HR DNA repair status of PCO culture with corresponding sensitivity to 10 mM Rucaparib.
PCO culture HR status Sensitivity to Rucaparib*
Group 1 Fresh collection Group 4 Frozen Group 1 Fresh collection Group 4 Frozen
58 + + R R
61 + + R R
63 + 2 R R
66 + + R R
69 + + R R
87 + + R R
88 + + R R
91 + + R R
60 2 2 S S
67 2 2 S S
68 2 2 S S
75 2 2 S S
77 2 2 S S
89 2 2 S S
90 2 2 S S
*Cell survival following 10 mM Rucaprib. Resistant (R) = more than 70% survival; Sensitive (S) = less than 70% survival.
doi:10.1371/journal.pone.0090604.t005
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biomarkers for treatments which depend upon the dysregulation of
a complete pathway as opposed to aberration of a single gene.
In conclusion therefore we have described the techniques for
collecting, transporting and culturing cells from patients with
ovarian cancer. We believe this to be safe and reliable and in our
opinion is a useful way of generating tissue for use both in
translational studies and potentially for functional diagnostic
testing.
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